BeiGeneius Hematology Summit – CLL
An expert multidisciplinary panel review the latest developments in CLL and the evolving role of BTK inhibitors via an interactive agenda including presentations, ‘Ask the Experts’ sessions and workshops.
Patient evaluation and risk stratification

First-line treatment for CLL: An evolving landscape

Treating relapsed/refractory CLL

CLL and the immune system: Infections, vaccines, and autoimmune disease

Cardiovascular toxicities associated with BTK inhibitors

Updates in CLL from ASH 2022
